Real-World Use of Pacritinib in Myelofibrosis: Results From the TriNetX Analysis on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Platelets ≥50 × 109/L at Initiation (TRIPAC) (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-1200; Location: LEVEL 3, HALL B3; "Among patients with prior JAK-inhibitor exposure, 95.8% (46 of 48) received ruxolitinib. In this real-world retrospective analysis of patients with MF and baseline PLT ≥50 × 109/L, treatment with pacritinib resulted in a notable proportion of patients who experienced increases in hematologic parameters at 6 months. These findings provide real-world evidence supporting pacritinib use in patients with MF and PLT ≥50 × 109/L at initiation. ACVR1: activin A receptor type 1 activity, IRAK1: interleukin-1 receptor-associated kinase 1, JAK1/2: Janus kinase 1/2, NR: not reached, OS: overall survival, PLT: platelet count."
Clinical • Real-world • Real-world evidence • Myelofibrosis • Oncology • ACVR1 • IRAK1 • JAK1
|
|
Ghaith Abu-Zeinah MD 1; Alex Coltoff MD 2; Erick Moyneur MA 3; Katherine Dea MSc 3; Michael Marrone PhD,MPH 4; Sara Bruce Wirta PhD 5; Faizan Sattar PharmD 4; Michael Vredenburg PhD 4; Andrew Srisuwananukorn MD 6
|